Background: Hepatitis B virus (HBV) 
Scientific background of the subject
Previously, HBsAg served as a qualitative diagnostic marker for hepatitis B infection. Quantitative serum HBsAg assays, including Abbott Architect and Roche Elecsys HBsAg assay, have been developed recently. Several recent studies suggest that quantification of HBsAg may be useful for clinical staging of chronic hepatitis B.
What this study adds to the field
The study presented revealed significantly good correlation between Abbott Architect and Roche Elecsys HBsAg assays. HBsAg quantification may potentially provide complementary information about the deduction of the natural course in chronic hepatitis B infection. H epatitis B virus (HBV) infection is a public health problem worldwide. There are more than 350 million HBV carriers in the world. [1] The prevalence of HBV carriers is 10-20% in high prevalence areas (Southeast Asia, China, sub-Saharan Africa). [2] In Taiwan, HBV is one of the infectious diseases of highest prevalence. People with chronic hepatitis B infection have an increased risk of developing cirrhosis or hepatocellular carcinoma. The estimated worldwide mortality is 0.5-1.2 million deaths per year. [3] Hepatitis B surface antigen (HBsAg), being a reflection of the transcriptional activity of cccDNA (covalently closed circular DNA) and integrated HBV DNA sequence, is produced through a complex mechanism. Previously, HBsAg served as a qualitative diagnostic marker for hepatitis B infection. Recently, quantitative serum HBsAg assays have been developed. [4, 5] Several recent studies suggest that quantification of HBsAg (qHBsAg) may be useful for clinical staging of chronic hepatitis B. [6, 7] HBsAg levels are highest during the immune-tolerant phase, when there are high levels of HBV replication, and lowest in the inactive (low replicative immune control) phase. [8] [9] [10] The aim of this study is to compare the two assays, Abbott Architect and Roche Elecsys II, and check whether the same results are obtained in the level of HBsAg in chronic hepatitis B patients, and to correlate the levels with the level of HBV DNA in HBeAg-positive or HBeAg-negative, treatment-naïve chronic hepatitis B patients.
METHODS

Patients and samples
This study was a cross-sectional study. From March 2012 to June 2012, a total of 90 chronic HBV-infected patients were enrolled in this study [ Table 1 ], which consisted of 68 males and 22 females, with a median age of 49.2 years (range 20.5-71.7 years). The patients signed informed consent and the study was conducted under the approval of Institutional Review Board, Chang Gung Memorial Hospital, Taiwan. Fifty-three of the patients were treatment-naïve and 37 of them were under treatment with interferon-based therapy or nucleos (t) ide analogs. The baseline characteristics of treatment-naive patients are listed in Table 2 and the characteristics of patients during treatment are listed in Table 3 . All patients were recruited from one medical center, Chang Gung Memorial Hospital, Lin-Kou, Taiwan. The time for checking HBsAg levels during treatment varied widely, especially our patients treated with Interferon-based or nucleos(t) ides analogs therapy. In the group of on-treatment patients, patients' HBsAg levels were measured with both assays at the same time.
HBsAg quantitation and HBV DNA
The Elecsys HBsAg assay (Roche Diagnostics GmbH, Mannheim, Germany) is a two-step sandwich chemiluminescent microparticle immunoassay. Briefly, the assay uses two biotinylated monoclonal HBsAg-specific capture antibodies together with a mixture of biotinylated and ruthenium-labeled polyclonal anti-HBsAg detection antibodies to form a sandwich complex with serum HBsAg. This complex is then bound to streptavidin-coated microparticles and, subsequently, ruthenium chemiluminescence is detected. [11] Results from the Elecsys HBsAg assay were generated in cut-off index and converted to WHO IU/ml.
The Architect assay (Abbott Diagnostics, Abbott Park, IL, USA) was performed following manufacturer's recommendations. After 1:100 dilution with the serum diluent provided by the manufacturer, samples with HBsAg levels > 250 IU/ml were retested at a dilution of 1:500 and 1:1000. Samples with HBsAg levels < 0.05 IU/ml at 1:100 dilution were retested undiluted. The Abbott Architect HBsAg assay is calibrated to give the results in IU/ml. [12] HBV DNA was analyzed by COBAS TaqMan HBV Test (Roche Molecular Diagnostics Products, USA). The lower limit of detection was 20 IU/ml.
Statistical methods
The data were presented as median and range values. Differences between subgroups were analyzed using Mann-Whitney U-test. Statistical significance was defined as a p value of less than 0.05. The linear regression model, Chi-square test, Spearman's rank correlation coefficient (denoted as γ s ), and Bland-Altman analysis were used to analyze the correlation between Elecsys assay and Architect assay. The data for Bland-Altman analysis were transformed to log (10) IU/ml. The bias was calculated as a percentage (%) of difference between two methods according to the formula: (Architect − Elecsys) ×100/average. Statistical analyses were performed using SPSS 17.0 statistical software and Prism 6.0 (GraphPad Software, Inc, CA, USA).
RESULTS
HBsAg levels in the serum samples from 90 patients with chronic hepatitis B were assessed in both Architect and Elecsys HBsAg assays, and the patients' characteristics are shown in Table 1 . The HBV DNA levels were also measured at the same time. There was a significantly good correlation between the Architect and Elecsys HBsAg assays in untreated patients (n = 53) and on-treatment patients (n = 37) with linear regression model, Spearman's rank correlation coefficient (denoted as γ s ) [ Figure 1 ], and Bland-Altman analysis [ Figure 2 ]. Moreover, HBsAg levels measured with the two assays correlated well in treatment-naïve patients (n = 53, γ s = 0.997) and on-treatment patients (n = 37, γ s = 0.988) [ Figure 1 ]. Bland-Altman analyses of the discrepancies in HBsAg levels between the Elecsys and the Architect assays showed a bias of −5.0% in all patients, −4.2% in untreated patients, and −6.2% in on-treatment patients. These study results were compatible with previous research studies which reported a good correlation between quantitative HBsAg measurements conducted with the Architect and the Elecsys assays. [4, 5] We analyzed the 53 treatment-naïve patients and divided them into HBeAg-positive and HBeAg-negative groups [ Table 2 ]. In Roche Elecsys assay, the median HBsAg level was 480.2 IU/ml, with a significantly higher level in HBeAg-positive than in HBeAg-negative patients (median 8934.5 vs. 239.1 IU/ml, p < 0.001). In Abbott Architect assay, the median level was 513.4 IU/ml, with a significantly higher level in HBeAg-positive than in HBeAg-negative patients (median 13,182.5 vs. 193.1 IU/ml, p < 0.001) [ Figure 3 ]. The median of HBV DNA level was lower in HBeAg-negative than in HBeAg-positive patients (0.02315 × 10 6 vs. 1.015505 × 10 6 IU/ml, p = 0.258). However, it revealed no significant difference between HBeAg-positive and HBeAg-negative groups, which might be due to the small sample size (HBV DNA level was detected and available in 29 patients, 5 of HBeAg-positive patients and 24 of HBeAg-negative patients).
We also analyzed all the parameters in on-treatment patients, except HBV DNA level [ Table 3 ]. The median HBsAg level was significantly lower in HBeAg-negative than in HBeAg-positive patients in both Architect and Elecsys HBsAg assays. The HBV DNA data of on-treatment patients were almost of low titer or undetectable.
Furthermore, HBeAg-positive treatment-naïve patients were found to be younger, which was compatible with a natural history of chronic hepatitis B infection. We assigned treatment-naïve patients into two groups of age less than 40 years (n = 17) as immune tolerance/clearance phase and greater than or equal to 40 years (n = 36) as residual inactive phase [ Table 4 ]. We applied two quantitative methods (Abbott Architect and Roche Elecsys HBsAg II assay) and measured HBV DNA in both groups for further analyses as shown in Figure 4 . The median HBsAg level was relatively higher in younger age (less than 40 years), but there was no statistically significant difference.
DISCUSSION
Measuring serum HBV DNA is the gold standard for monitoring viral load, but it is relatively costly and not available in some areas. The technique for detecting HBsAg quantification is relatively easy and inexpensive. Recent studies indicate that HBsAg quantification might be a useful complement to HBV DNA quantification for clinical assessment and treatment monitoring in patients with chronic HBV infection. [13, 14] Recent studies [15] [16] [17] and our study showed that HBsAg levels measured by the Roche Elecsys HBsAg II assay correlate well with those obtained using the established Abbott Architect assay. The Elecsys HBsAg II assay provides a reliable method for HBsAg quantitation in treatment-naïve and on-treatment patients. The HBsAg level is higher in HBeAg-positive patients, but HBV DNA level is not statistically significantly higher in HBeAg-positive patients which may be due to smaller sample size. In addition, the HBsAg quantification level may reflect the clinical stage and liver disease progression, and a combined use of quantification of HBsAg and HBV DNA may improve the understanding of clinical course.
Although serum HBsAg qualitative test is the standard procedure for HBV diagnosis, however, there has recently been an increased development in the use of quantitative testing as a predictor of response to treatment. [18] [19] [20] Clearance of HBsAg is associated with improved long-term clinical outcome, including a reduced incidence of cirrhosis and hepatocellular carcinoma and longer survival. [21, 22] Quantitative measurement of HBsAg is, therefore, likely to be of increasing importance as its use in individualization of therapy in HBV infection.
In conclusion, the Elecsys HBsAg II assay reliably determines serum HBsAg levels and its correlation with the Abbott Architect HBsAg assay is high. In clinical practice, Roche Elecsys II may have the possibility of improving the reproducibility of the analysis and lowering the work load of the technician, but a rigorous study design is needed to prove it. Both assays can, therefore, be applied for HBsAg quantification in clinical practice in different stages or treatment status. Moreover, HBsAg quantification may potentially provide complementary information about the deduction of the natural course in chronic hepatitis B infection. Further large-scale studies may be needed to make maximal use of HBsAg quantification to elucidate its role in clinical fields. 
